Nephritis / Glomerulonephritis / Interstitial Nephritis — Clinical Documentation Guide (2026)

🔍 Definition

Nephritis is a broad term encompassing inflammation of the kidney, primarily classified into two major anatomical patterns: glomerulonephritis (GN), affecting the glomeruli (the filtering units), and interstitial nephritis (tubulointerstitial nephritis), affecting the tubules and surrounding interstitium. These processes share the common pathophysiologic endpoint of impaired renal filtration but differ markedly in etiology, clinical presentation, and ICD-10-CM coding pathways.

Glomerulonephritis results from immune-mediated injury to the glomerular capillary tuft, manifesting as one of several histopathologic patterns (membranous, mesangial proliferative, endocapillary proliferative, mesangiocapillary, dense deposit disease, crescentic, etc.). Clinical syndromes include acute nephritic syndrome, rapidly progressive GN (RPGN), recurrent/persistent hematuria, chronic nephritic syndrome, and nephrotic syndrome — each corresponding to distinct ICD-10-CM subcategories (N00–N07) with morphology-specific fourth-character digits.

Interstitial nephritis involves inflammation of the tubulo-interstitial compartment, often triggered by drugs (NSAIDs, antibiotics, proton pump inhibitors), infections, obstructive uropathy, or metabolic disorders. Acute interstitial nephritis (AIN) may present as AKI; chronic interstitial nephritis (CIN) progresses to CKD. ICD-10-CM codes N10–N16 capture the spectrum from acute pyelonephritis to drug-induced tubular damage.

Accurate documentation requires the clinician to specify: (1) the clinical syndrome (nephritic vs. nephrotic, acute vs. chronic, recurrent vs. rapidly progressive); (2) the morphologic pattern on biopsy when available; (3) the underlying etiology (diabetic, lupus, hypertensive, drug-induced, hereditary); and (4) the presence and stage of CKD or AKI. Each of these dimensions drives ICD-10-CM code selection, HCC capture, and MS-DRG assignment.

🗂️ Alternative Terminology

🩺 Signs & Symptoms

Clinical presentations vary by syndrome and must be explicitly documented to support specific coding:

• Nephritic syndrome features (N00, N01, N03, N05): Hematuria (gross or microscopic with RBC casts), oliguria, hypertension, edema (periorbital, dependent), azotemia, proteinuria (sub-nephrotic range <3.5 g/day). In RPGN (N01), renal function declines by ≥50% over weeks.
• Nephrotic syndrome features (N04): Heavy proteinuria ≥3.5 g/day, hypoalbuminemia (<3.5 g/dL), edema (anasarca, ascites, pleural effusion), hyperlipidemia, lipiduria (oval fat bodies, fatty casts). Thrombophilia risk (renal vein thrombosis).
• Recurrent/persistent hematuria (N02): Episodic gross hematuria (often with upper respiratory infections in IgA nephropathy), persistent microscopic hematuria, flank discomfort, mild proteinuria.
• Interstitial nephritis (N10–N12): AIN classic triad of fever, rash, eosinophilia (now recognized in <10% of cases); AKI with sterile pyuria, eosinophiluria, subnephrotic proteinuria, tubular dysfunction (Fanconi syndrome). Chronic interstitial nephritis presents with slowly progressive CKD, hyperkalemia, non-anion gap metabolic acidosis, polyuria.
• Pyelonephritis (N10): Flank pain, costovertebral angle tenderness, fever, chills, dysuria, frequency, bacteriuria/pyuria on urinalysis.
• Drug-induced nephropathy (N14.x): Sudden rise in serum creatinine following introduction of offending drug, non-oliguric AKI, tubular casts, hyperkalemia.

🧭 Differential Diagnosis

📋 Clinical Indicators for Coders/CDI

🦴 Anatomy & Pathophysiology

The kidney contains approximately 1 million nephrons per organ, each comprising a glomerulus and a tubule. The glomerulus — a specialized capillary tuft enclosed in Bowman's capsule — filters approximately 180 L of plasma per day, driven by hydrostatic pressure. The filtration barrier consists of three layers: fenestrated glomerular endothelium, the glomerular basement membrane (GBM), and podocytes with their slit diaphragms. Disruption to any of these layers by immune deposits, antibodies, or cytokines initiates the glomerulonephritis cascade.

Glomerulonephritis Pathophysiology: In immune-complex GN (IgA nephropathy, lupus nephritis, post-infectious GN), immune complexes deposit in the mesangium, subendothelial, or subepithelial spaces, activating complement (C3a, C5a), recruiting neutrophils and monocytes, and triggering mesangial/endothelial cell proliferation. In anti-GBM disease, linear IgG antibodies against the NC1 domain of collagen IV directly attack the GBM. In ANCA-associated GN, activated neutrophils degranulate within glomerular capillaries, producing necrotizing lesions and crescent formation (parietal epithelial cell proliferation into Bowman's space — the hallmark of RPGN).

Tubulo-Interstitial Pathophysiology: Drug-induced AIN is a type IV hypersensitivity reaction in which a hapten-drug complex bound to tubular antigens recruits T-lymphocytes, causing tubular epithelial injury and interstitial edema. Ischemic or nephrotoxic AKI disrupts proximal tubular epithelium, causing ATN (N17.0) with tubular cell sloughing and cast obstruction. Chronic interstitial nephritis leads to tubular atrophy, interstitial fibrosis, and ultimately nephron loss with progressive CKD. In obstructive nephropathy (N13.x), increased intratubular pressure causes tubular dilation, collecting system distension, and — if sustained — irreversible medullary and cortical damage.

Etiology/Manifestation Principle: ICD-10-CM recognizes that many nephritides are manifestations of systemic disease. Under the FY2026 ICD-10-CM Official Guidelines, certain conditions require the underlying disease to be sequenced first (e.g., code M32.14 before N08 for lupus nephritis; code E11.21/E11.22 as the combination code for diabetic nephropathy, not N08).

💊 Medication Impact / Treatment

Pharmacotherapy for nephritis conditions has direct coding implications — both for HCC validation through treatment patterns and for adverse effect/underdosing codes when drug-induced nephropathy is present.

Immunosuppressive and Biologic Therapies

• Corticosteroids (prednisone, methylprednisolone): First-line for MCD, FSGS, acute interstitial nephritis, lupus nephritis flare. Long-term use requires documentation of complications (osteoporosis, diabetes, adrenal insufficiency).
• Mycophenolate mofetil (MMF): Induction and maintenance for lupus nephritis (Class III–V); used in FSGS and MCD steroid-dependent cases.
• Cyclophosphamide: Induction therapy for ANCA vasculitis GN, severe lupus nephritis; high-dose IV or oral protocols.
• Rituximab (J9312): Anti-CD20 biologic for ANCA-GN, membranous nephropathy (PLA2R+), refractory lupus nephritis.
• Belimumab (J0490): FDA-approved 2020 specifically for active lupus nephritis; IV formulation; HCPCS J0490.
• Anifrolumab (J0491): Type I interferon receptor antagonist; approved for moderate-to-severe SLE including lupus nephritis manifestations.
• Tacrolimus / Cyclosporine: Calcineurin inhibitors used in steroid-resistant FSGS and membranous nephropathy.
• Voclosporin (Lupkynis): Calcineurin inhibitor FDA-approved 2021 specifically for active lupus nephritis in combination with MMF.

RAAS Blockade and Nephroprotection

• ACE inhibitors / ARBs: Mandatory in proteinuric CKD (diabetic and non-diabetic nephropathy) to reduce intraglomerular pressure and proteinuria. Underdosing or discontinuation despite proteinuria should be queried.
• SGLT2 inhibitors (dapagliflozin, empagliflozin): FDA-approved 2020–2021 for CKD with or without T2DM; reduce progression in IgA nephropathy (dapagliflozin 2023 approval) and FSGS (investigational).
• Sparsentan: Dual endothelin/angiotensin receptor antagonist; FDA-approved 2023 for IgA nephropathy.
• Iptacopan: Factor B inhibitor; FDA-approved 2024 for paroxysmal nocturnal hemoglobinuria nephropathy and C3 glomerulopathy.

Supportive Agents

• Furosemide / torsemide: Management of nephrotic edema and volume overload in advanced CKD.
• ESAs (epoetin alfa Q4081, darbepoetin J0882): Anemia of ESRD/CKD; covered under ESRD dialysis bundle or separately billed per HCPCS codes.
• Phosphate binders, vitamin D analogs, calcimimetics: Mineral bone disorder management in advanced CKD/ESRD.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides